<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Coeptis Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc</link>
<description>Latest news and press releases for Coeptis Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 15:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/coeptis-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835580e78dffbe2df0ea71a.webp</url>
<title>Coeptis Therapeutics Inc</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc</link>
</image>
<item>
<title>Z Squared Provides Additional Information on Previously Disclosed Pro Rata Distribution</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/z-squared-provides-additional-information-on-previously-disclosed-pro-rata-distribution</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/z-squared-provides-additional-information-on-previously-disclosed-pro-rata-distribution</guid>
<pubDate>Mon, 27 Apr 2026 15:30:00 GMT</pubDate>
<description>Z Squared, Inc. (NASDAQ: ZSQR) ("Company") today issued supplemental information related to its previously announced business combination with Coeptis Therapeutics Holdings, Inc. and its pro rata dividend distribution related to Coeptis Therapeutics Holdings, Inc.'s pre-business combination biopharmaceutical business. The Company announced that the pro rata distribution of shares held by the Company in its subsidiary Coeptis Holdings, Inc. will be issued to shareholders of record on January 2, 2</description>
</item>
<item>
<title>Z Squared Announces Completion of Business Combination with Coeptis Therapeutics and Listing on the Nasdaq Global Market</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/z-squared-announces-completion-of-business-combination-with-coeptis-therapeutics-and-listing-on-the-nasdaq-global-market</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/z-squared-announces-completion-of-business-combination-with-coeptis-therapeutics-and-listing-on-the-nasdaq-global-market</guid>
<pubDate>Fri, 24 Apr 2026 20:43:00 GMT</pubDate>
<description>Z Squared, Inc. (Nasdaq: ZSQR) ("Z Squared" or the "Company"), a vertically integrated computing infrastructure company, today announced the completion of its business combination with Coeptis Therapeutics Holdings, Inc. ("Coeptis"). In connection with the business combination, the combined company has been renamed "Z Squared Inc." and its public shares are expected to commence trading on the Nasdaq Global Market under the ticker symbol "ZSQR" on Monday, April 27, 2026 (CUSIP: 98878K108).</description>
</item>
<item>
<title>Coeptis Announces Approval of Z Squared Inc.’s Nasdaq Listing Application</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-announces-approval-of-z-squared-incs-nasdaq-listing-application</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-announces-approval-of-z-squared-incs-nasdaq-listing-application</guid>
<pubDate>Tue, 07 Apr 2026 04:00:00 GMT</pubDate>
<description>~ Approval Marks Satisfaction of Key Closing Condition in Pending Merger ~ WEXFORD, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings,</description>
</item>
<item>
<title>Coeptis Receives Shareholder Approval Towards Z Squared Merger</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-receives-shareholder-approval-towards-z-squared-merger</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-receives-shareholder-approval-towards-z-squared-merger</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>Shareholder Approval Clears a Key Condition to Close WEXFORD, Pa., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP)</description>
</item>
<item>
<title>Vanderbilt Report: Coeptis Therapeutics Shareholders Approve Transformational Merger: From Biopharma to Dual-Sector Platform</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/vanderbilt-report-coeptis-therapeutics-shareholders-091500469</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/vanderbilt-report-coeptis-therapeutics-shareholders-091500469</guid>
<pubDate>Wed, 04 Feb 2026 09:15:00 GMT</pubDate>
<description>BRISTOL, TN / ACCESS Newswire / February 4, 2026 / Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) shareholders approved a transformational merger that converts a clinical-stage biopharmaceutical company into a dual-sector enterprise. The transaction ...</description>
</item>
<item>
<title>Coeptis Therapeutic Holdings Details $835M Transaction Structure with Z-Squared; Vanderbilt Report Publishes Coverage</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-therapeutic-holdings-details-dollar835m-transaction-structure-with-z-squared-vanderbilt-report-publishes-coverage</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-therapeutic-holdings-details-dollar835m-transaction-structure-with-z-squared-vanderbilt-report-publishes-coverage</guid>
<pubDate>Tue, 06 Jan 2026 13:31:00 GMT</pubDate>
<description>BRISTOL, TN / ACCESS Newswire / January 6, 2026 /The Vanderbilt Report today published coverage of Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) following the company's recent SEC filings detailing a merger transaction with Z-Squared, Inc. According ...</description>
</item>
<item>
<title>Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-therapeutics-s-4-declared-effective-by-sec-proxy-mailing-begins-in-anticipation-of-the-merger-transaction-with-z-squared</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-therapeutics-s-4-declared-effective-by-sec-proxy-mailing-begins-in-anticipation-of-the-merger-transaction-with-z-squared</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>~ Annual/Special Meeting of Shareholders to be Held on January 30, 2026 ~ WEXFORD, Pa., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc.</description>
</item>
<item>
<title>Coeptis Anchors $800M Valuation in Dual-Sector Strategy; Vanderbilt Report Publishes Coverage</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-anchors-dollar800m-valuation-in-dual-sector-strategy-vanderbilt-report-publishes-coverage</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-anchors-dollar800m-valuation-in-dual-sector-strategy-vanderbilt-report-publishes-coverage</guid>
<pubDate>Wed, 01 Oct 2025 04:00:00 GMT</pubDate>
<description>BRISTOL, TN / ACCESS Newswire / October 1, 2025 / Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) today announced that The Vanderbilt Report has published</description>
</item>
<item>
<title>Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-coep-extinguishes-convertible-note-123600900</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-coep-extinguishes-convertible-note-123600900</guid>
<pubDate>Tue, 22 Jul 2025 12:36:00 GMT</pubDate>
<description>WEXFORD, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and biopharmaceutical company, is pleased to announce the extinguishment of its convertible note with YA II PN, Ltd (“Yorkville”). The extinguishment of this convertible note, dated January 16, 2025, has cleared the Company’s outstanding debt obligations to Yorkville. David Mehalick, CEO of Coeptis Therapeutics Holdings, Inc., stated, “The extingu</description>
</item>
<item>
<title>Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-coep-announces-filing-of-registration-statement-on-form-s-4-with-sec-in-connection-with-proposed-transaction-with-z-squared</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-coep-announces-filing-of-registration-statement-on-form-s-4-with-sec-in-connection-with-proposed-transaction-with-z-squared</guid>
<pubDate>Thu, 26 Jun 2025 04:00:00 GMT</pubDate>
<description>WEXFORD, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (“Coeptis” or the “Company”), a next-gen technology and</description>
</item>
<item>
<title>Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/monarch-therapeutics-snap-biosciences-inc-122800832</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/monarch-therapeutics-snap-biosciences-inc-122800832</guid>
<pubDate>Wed, 28 May 2025 12:28:00 GMT</pubDate>
<description>WEXFORD, Pa. and PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) and Monarch Therapeutics Inc., a biotechnology company pioneering next-generation immunotherapies, today announced a licensing agreement to enable the development and commercialization of SNAP Biosciences’ proprietary Snap-Car NK cell therapy platform in oncology using Monarch’s small molecule adaptor technology. This agreement</description>
</item>
<item>
<title>Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-therapeutics-inc-and-z-squared-inc-announce-merger-agreement</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-therapeutics-inc-and-z-squared-inc-announce-merger-agreement</guid>
<pubDate>Fri, 25 Apr 2025 04:00:00 GMT</pubDate>
<description>Aim to create the largest publicly-traded, Dogecoin-focused mining company in the world Coeptis to spin out biopharmaceutical operations WEXFORD, Pa., April</description>
</item>
<item>
<title>COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-partners-with-nexgenai-solutions-group-to-launch-new-ai-co-working-hub-in-india-driving-global-innovation-in-technology</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-partners-with-nexgenai-solutions-group-to-launch-new-ai-co-working-hub-in-india-driving-global-innovation-in-technology</guid>
<pubDate>Thu, 17 Apr 2025 04:00:00 GMT</pubDate>
<description>Strategic Collaboration Enhances Access to Cutting-Edge AI, Blockchain Solutions, Biopharma & Defense Technologies WEXFORD, Pa., April 17, 2025 (GLOBE</description>
</item>
<item>
<title>Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR™ Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-therapeutics-secures-worldwide-development-123400980</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-therapeutics-secures-worldwide-development-123400980</guid>
<pubDate>Tue, 11 Mar 2025 12:34:00 GMT</pubDate>
<description>• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities. WEXFORD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced it has successfully licensed exclusive worldwide development and commercialization right</description>
</item>
<item>
<title>COEPTIS’ NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-nexgenai-affiliates-partners-nuburu-133700828</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-nexgenai-affiliates-partners-nuburu-133700828</guid>
<pubDate>Fri, 07 Mar 2025 13:37:00 GMT</pubDate>
<description>Leveraging Advanced AI and Robotics to Revolutionize Marketing Strategies in Defense and Security SectorsWEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS’ NexGenAI Affiliates Network “NexGen” and NUBURU, Inc. “NUBURU” (NYSE: BURU), a leading innovator in high-power blue laser technology. This collabor</description>
</item>
<item>
<title>COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-nexgenai-affiliates-network-marketleverage-122700809</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-nexgenai-affiliates-network-marketleverage-122700809</guid>
<pubDate>Thu, 20 Feb 2025 12:27:00 GMT</pubDate>
<description>This partnership gives COEPTIS access to AI-driven campaign management, predictive analytics, and automated outreach capabilities with MarketLeverage’s 5,500 advertisers and 55,000 publishers, creating one of the most expansive and effective affiliate networks in the industryWEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is thrilled to announce a partne</description>
</item>
<item>
<title>COEPTIS’ NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-nexgenai-partners-with-arketyp-valu-to-revolutionize-digital-engagement-on-the-verus-network</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-nexgenai-partners-with-arketyp-valu-to-revolutionize-digital-engagement-on-the-verus-network</guid>
<pubDate>Thu, 20 Feb 2025 05:00:00 GMT</pubDate>
<description>The Strategic Collaboration Integrates Cutting-Edge Marketing Tools into the ValuSocial Platform, Leveraging the Robust Capabilities of Verus Coin and</description>
</item>
<item>
<title>COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-announces-the-launch-of-coep-venture-group-to-invest-in-ai-rpa-and-ai-agent-startups</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-announces-the-launch-of-coep-venture-group-to-invest-in-ai-rpa-and-ai-agent-startups</guid>
<pubDate>Thu, 13 Feb 2025 05:00:00 GMT</pubDate>
<description>WEXFORD, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to</description>
</item>
<item>
<title>COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-completes-dollar10-million-series-a-preferred-financing-round-reinforcing-commitment-to-technological-innovation-and-ai-integration</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-completes-dollar10-million-series-a-preferred-financing-round-reinforcing-commitment-to-technological-innovation-and-ai-integration</guid>
<pubDate>Thu, 06 Feb 2025 05:00:00 GMT</pubDate>
<description>WEXFORD, Pa., Feb. 6, 2025 /PRNewswire/ -- COEPTIS, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a pioneering technology company dedicated to advancing</description>
</item>
<item>
<title>Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation</title>
<link>https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-therapeutics-holdings-becomes-coeptis-embracing-a-future-of-technology-and-innovation</link>
<guid isPermaLink="true">https://6ix.com/company/coeptis-therapeutics-inc/news/coeptis-therapeutics-holdings-becomes-coeptis-embracing-a-future-of-technology-and-innovation</guid>
<pubDate>Thu, 30 Jan 2025 05:00:00 GMT</pubDate>
<description>Rebranding Signals Strategic Shift Beyond Biopharmaceuticals, Highlights Commitment to Technology, Artificial Intelligence and Shareholder Value WEXFORD, Pa.,</description>
</item>
</channel>
</rss>